Shionogi announced that the U.S. FDA has approved XOCOVA (ensitrelvir) for post-exposure prophylaxis of COVID-19 in adults and adolescents 12 and older, making it the first and only oral option to prevent COVID-19 after exposure in today’s therapeutic landscape.

In trials, common side effects included headache, diarrhea, and cough, with a safety profile showing no deaths attributed to the drug and manageable adverse events.

The primary endpoint demonstrated a 67% reduction in the risk of developing PEP symptoms by day 10 for the 125 mg dose versus placebo, and the median time to symptom resolution favored 125 mg (approximately 168 hours) over placebo (about 192 hours).

The company cited June 1, 2026, as the date of the announcement, with details attributed to the article author and publication.

The reporting article notes a May 31, 2026 publication date and identifies Reuters as the source of the formal news coverage.

The piece links to related Endpoints articles and references broader FDA news, industry moves, and ongoing prompts for subscriptions and promotions.

Forward-looking statements warn of risks, uncertainties, and regulatory considerations that could affect future outcomes.

Disclosures acknowledge typical regulatory, manufacturing, and market risks that could influence the eventual uptake and use of the therapy.

The NEJM article by Hayden et al. details the SCORPIO-PEP study data, with Shionogi emphasizing the practical importance of post-exposure prophylaxis in real-world settings.

Market context notes include a YTD stock performance, trading volume, and a Buy sentiment, alongside Shionogi’s approximate market capitalization.

Shionogi’s broader profile includes roughly 4,955 employees and a global focus on R&D, manufacturing, and marketing across multiple regions.

The approval came ahead of the PDUFA action date and suggests potential use beyond households, including nursing homes, care facilities, and travel-related exposures.